

Fensolvi[®] (leuprolide acetate) – New drug approval

- On May 4, 2020, [Tolmar Pharmaceuticals announced](#) the FDA approval of [Fensolvi \(leuprolide acetate\)](#), for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP).
- Other injectable formulations of leuprolide acetate are also available [generically](#) and as branded [Lupron Depot-PED[®]](#) and [Eligard[®]](#).
 - Generic leuprolide acetate and Eligard are approved for palliative treatment of advanced prostate cancer.
 - Lupron Depot-PED is approved for treatment of children with CPP.
- The efficacy of Fensolvi was established in an uncontrolled, open-label, single-arm study in 64 pediatric patients with CPP. Fensolvi reduced stimulated and basal gonadotropins to prepubertal levels.
 - Suppression of peak stimulated luteinizing hormone concentrations to < 4 IU/L was achieved in 87% of pediatric patients by month 6 and in 86% of patients by month 12.
 - Suppression of estradiol or testosterone concentration to prepubertal levels at the 6-month assessment was achieved in 97% and 100% of patients, respectively. Suppression of estradiol or testosterone was maintained at the 12-month assessment with 98% (55/56 females) and 50% (1/2 males) maintaining suppression.
 - Fensolvi arrested or reversed progression of clinical signs of puberty with reductions in growth velocity and bone age.
- Fensolvi is contraindicated in patients with:
 - Hypersensitivity to gonadotropin releasing hormone (GnRH), GnRH agonists or any of the components of Fensolvi. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported
 - Pregnancy
- Warnings and precautions for Fensolvi include initial rise of gonadotropins and sex steroid levels, psychiatric events, and convulsions.
- The most common adverse reactions ($\geq 5\%$) with Fensolvi use were injection site pain, nasopharyngitis, pyrexia, headache, cough, abdominal pain, injection site erythema, nausea, constipation, vomiting, upper respiratory tract infection, bronchospasm, productive cough, and hot flush.
- The recommended dose of Fensolvi is 45 mg administered by subcutaneous injection once every six months.
 - Fensolvi treatment should be discontinued at the appropriate age of onset of puberty.
 - Fensolvi must be administered by a healthcare professional.

- Tolmar Pharmaceuticals' launch plans for Fensolvi are pending. Fensolvi will be available as a 45 mg powder for suspension supplied in a kit.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.